News Grower

Independent coverage of AI, startups, and technology.

Ars Technica Apr 24, 2026 at 21:11 Big Tech Stable Warm

Europe—not US—first to authorize Moderna's combo mRNA flu-COVID vaccine

Amid RFK Jr.'s anti-vaccine agenda, Moderna withdrew its FDA application last year.

Signal weather

Stable

The story has moved beyond the first headline and now acts as a reliable context anchor.

By Beth Mole Original source
Europe—not US—first to authorize Moderna's combo mRNA flu-COVID vaccine

Moderna's mRNA-based combination vaccine against both flu and COVID-19 has gotten the green light in Europe—but it continues to be shelved in the US, where it was developed. This week, the European Commission authorized Moderna to market the vaccine, mRNA-1083 or mCOMBRIAX, making it the world's first authorized combination shot for the two respiratory viruses. The decision follows a positive review in February from a key European Medicines Agency's committee, which paved the way for the approval. Moderna CEO Stéphane Bancel welcomed the news. "By combining protection against two significant respiratory viruses in a single dose, our vaccine aims to simplify immunization for adults, particularly those at high risk," Bancel said in a press release. "mCOMBRIAX offers an important new option for Europeans, while also aiming to strengthen the resilience of healthcare systems across Europe."Read full article Comments

Stay on the signal

Follow Europe—not US—first to authorize Moderna's combo mRNA flu-COVID vaccine

Follow this story beyond a single article: new follow-ups, adjacent sources, and the evolving storyline.

We send a confirmation link first, then only meaningful digests.

Story map

Understand this topic fast

A quick entry into the story: why it matters now, who is involved, and where to go next for context.

Why it matters now

This story is still moving and pulling follow-up coverage.
There are already 6 connected articles in the same storyline to continue from here.
The story keeps orbiting around Amid RFK Jr, Anti Vaccine, and Anti Vaccine Agenda, so the entity pages are the fastest way to build context.
Ars Technica already has 4 follow-up stories on the same theme.

Topic constellation

Open the live map for this story

See which entities, story threads, sources, and follow-up articles shape this story right now.

Click nodes to continue

Entity Cluster Article Hub Source

Story timeline

Continue with this story

A short sequence of events and follow-up stories to understand the arc quickly.

Jun 9, 2026 at 21:05 Ars Technica

Starlink charges $10 monthly hardware fee in move away from one-time purchases

Starlink, SpaceX's top moneymaker, also raised service prices by $5 to $10.

Jun 9, 2026 at 20:56 Ars Technica

Locked in heated rivalry with researcher, Microsoft fixes 0-day they disclosed

A separate zero-day also disclosed by Nightmare Eclipse appears to be patched as well.

Jun 9, 2026 at 20:35 Ars Technica

Three key vital signs make up the "urban pulse" of a city

Cities are dynamic, not static grids, and urbanization is a "spiky," cyclical, and asynchronous process.

Jun 9, 2026 at 20:25 Ars Technica

Commonwealth Fusion makes the physics case for its 400 MW reactor

Five peer-reviewed papers update the design and model its expected output.

Jun 9, 2026 at 20:15 Ars Technica

Paramount accuses Netflix of "scorched-earth campaign" against WBD merger

Netflix's response: "Absurd."

Apr 24, 2026 at 21:11 Ars Technica

Europe—not US—first to authorize Moderna's combo mRNA flu-COVID vaccine

Amid RFK Jr.'s anti-vaccine agenda, Moderna withdrew its FDA application last year.

How reliable this looks

Signal and trust for Ars Technica

This source works at a rapid pace: 100% of recent stories land in the hot window, and 0% carry visible search signal.

Trusted

Reliability

92

Freshness

100

Sources in storyline

1

Related articles

More stories that share tags, source, or category context.

More from Ars Technica

Fresh reporting and follow-up coverage from the same newsroom.

Open source page